Harmony Biosciences Holdings, Inc. (HRMY) Stock Grade

About Harmony Biosciences Holdings, Inc.'s fundamentals

Harmony Biosciences generates revenue with strong profitability, posting an 18.3% net margin and 18.2% return on equity, indicating efficient conversion of sales into earnings and shareholder value. The company's 21.5% year-over-year revenue growth outpaces typical biotech expansion rates, suggesting robust demand for its offerings. Trading at a P/E ratio of 13.6, the company carries a relatively modest valuation relative to its profitability, though investors should note there is no dividend yield, meaning returns depend entirely on capital appreciation or future distribution decisions.